Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
Polyglutamine (polyQ) ataxias are a heterogenous group of neurological disorders all caused by an expanded CAG trinucleotide repeat located in the coding region of each unique causative gene. To date, polyQ ataxias encompass six disorders: spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 and accou...
Guardado en:
Autores principales: | Craig S. McIntosh, Dunhui Li, Steve D. Wilton, May T. Aung-Htut |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2ca7d2f150f42ffa71be3091986a353 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Spinocerebellar ataxia type 40: A case report and literature review
por: Han Fengyue, et al.
Publicado: (2021) -
Oligonucleotides
Publicado: (2003) -
Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation
por: Prithi Raguraman, et al.
Publicado: (2021) -
Tritium labeling of antisense oligonucleotides via different conjugation agents
por: Martin R. Edelmann, et al.
Publicado: (2021) -
Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
por: Wioleta Grabowska-Pyrzewicz, et al.
Publicado: (2021)